upadacitinib · Rinvoq
Small molecule
Also known as ABT-494
Evidence outlook
Approved: Atopic Dermatitis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis (label: moderately to severely active UC or CD who have had an inadequate response, lost response or were...), Rheumatoid Arthritis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Systemic Lupus Erythematosus · Phase 3Vitiligo · Phase 3 · filing submittedHidradenitis Suppurativa · Phase 3Alopecia Areata · Phase 3 · filing submitted
Also approved (11)
- Ankylosing Spondylitis RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers.
- Non-radiographic Axial Spondyloarthritis RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy.
- Polyarticular Juvenile Idiopathic Arthritis RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an inadequate response or intolerance to one or more TNF blockers.
- Giant Cell Arteritis RINVOQ is indicated for the treatment of adults with giant cell arteritis.
- Severe alopecia areata in adults and adolescents 12 years and older (Rinvoq)
- Marketing authorisation of Rinvoq (first indication RA); current EU label includes ulcerative colitis and Crohn's disease
- Non-segmental vitiligo in adults and adolescents 12 years and older who are candidates for systemic therapy (Rinvoq)
- Moderately to severely active Crohn's disease with inadequate response to existing therapy
- Moderately to severely active ulcerative colitis with inadequate response to existing therapy
- Moderately to severely active ulcerative colitis and Crohn's disease
- Rheumatoid Arthritis RINVOQ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. RINVOQ may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs). Psoriatic Arthritis RINVOQ is indicated for the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other DMARDs. RINVOQ may be used as monotherapy or in combination with...
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
SELECT-NEXT NCT02675426 · Rheumatoid Arthritis This was a randomized, quadruple-blind, placebo-controlled trial in 661 patients using two validated rheumatoid arthritis disease-activity measures as co-primary endpoints, and both upadacitinib doses produced significantly higher response rates than placebo on both measures (all comparisons p<0.001). Registry: NCT02675426 | 3 | Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12); Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12 2017-04-21 | ACR20 at Week 12 (SELECT-NEXT): 64% (141/221) upadacitinib 15mg, 66% (145/219) upadacitinib 30mg, vs 36% (79/221) placebo; p<0.0001 for each dose vs placebo | Reliable signal | link ↗ |
View 5 more trials
SELECT-EARLY NCT02706873 · Rheumatoid Arthritis Participants were randomized and the study was quadruple-blinded (participant, care provider, investigator and outcomes assessor all masked), with methotrexate as an active comparator in over 1,000 patients. The primary comparisons -- ACR50 response at week 12 and DAS28(CRP)-based remission at week 24, both validated measures of rheumatoid arthritis disease activity -- were clearly met, with upadacitinib outperforming methotrexate by roughly 24 to 32 percentage points (p<0.001 for both doses). Registry: NCT02706873 | 3 | Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 - Global Analysis (Baseline and Week 12); Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 24 - Global Analysis; Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 - Global Analysis (Baseline and Week 12); Change From Baseline in Modified Total Sharp Score (mTSS) at Week 24 - Global Analysis (Baseline to Week 24) 2018-03-15 | Co-primary endpoints: ACR50 at Week 12 -- upadacitinib 15mg 52% (95% CI 47-58), 30mg 56% (95% CI 51-62), MTX 28% (95% CI 23-33), P<0.001 for both doses vs MTX. DAS28-CRP<2.6 at Week 24 -- upadacitinib 15mg 48% (95% CI 43-54), 30mg 50% (95% CI 45-56), MTX 19% (95% CI 14-23), P<0.001 for both doses vs MTX | Reliable signal | link ↗ |
NCT03086343 NCT03086343 · Rheumatoid Arthritis (RA) Participants were randomized and the trial was quadruple-blinded, comparing oral upadacitinib 15 mg to intravenous abatacept, an active biologic comparator, in 612 evaluable rheumatoid arthritis patients. The primary comparison -- change in the validated DAS28(CRP) disease activity score at week 12 -- met its pre-specified non-inferiority margin, and the 95% confidence interval for the treatment difference fell entirely on the side favoring upadacitinib. Registry: NCT03086343 | 3 | Change From Baseline in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Non-inferiority) (Baseline and Week 12) 2019-06-13 | Change from baseline DAS28-CRP at week 12: -2.52 (95% CI -2.66 to -2.37) upadacitinib vs -2.00 (95% CI -2.14 to -1.85) abatacept; upadacitinib met primary non-inferiority and key secondary superiority endpoints. | Reliable signal | link ↗ |
SELECT-MONOTHERAPY NCT02706951 · Rheumatoid Arthritis This was a randomized, double-blind trial of 648 patients that compared upadacitinib with an active comparator (continued methotrexate) using matching placebos. A power calculation planned 600 patients and 648 were enrolled, and both upadacitinib doses beat methotrexate on both primary endpoints, ACR20 response and DAS28-CRP low disease activity at week 14 (adjusted p<0.001). Registry: NCT02706951 | 3 | Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14 (Baseline and week 14); Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 14 2017-10-02 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
SELECT-COMPARE NCT02629159 · Rheumatoid Arthritis Participants were randomly assigned and fully blinded to upadacitinib, placebo or adalimumab, and upadacitinib beat placebo on both primary endpoints at week 12, ACR20 response and DAS28-CRP remission (both p<0.001). The protocol's sample-size calculation planned 1,500 participants, and 1,629 were enrolled. Registry: NCT02629159 | 3 | Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12); Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12 2017-10-27 | Primary results reported. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
SELECT-BEYOND NCT02706847 · Rheumatoid Arthritis Participants were randomly assigned and fully blinded to upadacitinib 15 mg, 30 mg or placebo, and both doses beat placebo at week 12 on ACR20 response (64.6% and 56.4% vs 28.4%) and on DAS28-CRP low disease activity (both p<0.001). The protocol's sample-size calculation planned 450 participants, and 499 were enrolled. Registry: NCT02706847 | 3 | Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12); Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12 2017-04-03 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (47)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (3)
What this study did
What this study did
What this study did
Phase 2 (21)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (19)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 2 (1)
What this study did
Competitive landscape
Other JAK drugs
baricitinib, tofacitinib, filgotinib, ivarmacitinib, QLM3003 and 1 more. Compare all 7 JAK drugs
Other JAK1 drugs
abrocitinib, filgotinib, LW402, VC005, Zemprocitinib and 3 more. Compare all 9 JAK1 drugs
This mechanism is crowded: 15 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Alopecia Areata: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Upadacitinib (Rinvoq): this drug | Phase 3 | Small molecule | JAK, JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Ivarmacitinib | Phase 3(overall) | Small molecule | JAK | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Jaktinib (Zepuping) | Phase 3 | Small molecule | JAK1/2/3 | Partial signal | NCT05051761: Primary endpoint, SALT score <=20 at week 24: both jaktinib doses superior to placebo (p<0.0001) (2024-06-13). | |
| Bempikibart | Phase 2 | Monoclonal antibody | IL-7 receptor alpha | Partial signal | NCT06018428: Part A primary, mean relative percent change in SALT score at week 24 vs placebo: the planned primary analysis was not performed after one site was excluded for protocol violations, so no primary-analysis result exists. Post-hoc per-protocol analysis (SALT 50-100): bempikibart (n=23) 16% mean reduction vs placebo (n=4) 2% reduction; Wilcoxon rank sum p=0.045. Part B is single-arm and has no comparison. | |
| Rezpegaldesleukin | Phase 2 | Protein / enzyme therapeutic | IL-2 mutein (Treg-selective) | not yet graded | No reviewed efficacy summary in this indication | |
| AZD0449 | Phase 1(overall) | — | JAK1 | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Londamocitinib | Discontinued | Small molecule | JAK1 | Partial signal(overall) | No reviewed efficacy summary in this indication |
Compare side by side
5 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(47 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Rinvoq (upadacitinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (6)
November 2026 (1)
What to watch
December 2026 (5)
What to watch
What to watch
What to watch
What to watch
2027 (15)
January 2027 (1)
What to watch
March 2027 (3)
What to watch
What to watch
What to watch
May 2027 (2)
June 2027 (2)
July 2027 (3)
What to watch
What to watch
What to watch
September 2027 (1)
What to watch
November 2027 (2)
December 2027 (1)
What to watch
2028 (13)
January 2028 (1)
What to watch
March 2028 (1)
What to watch
April 2028 (1)
What to watch
May 2028 (1)
What to watch
August 2028 (4)
What to watch
What to watch
What to watch
What to watch
September 2028 (2)
December 2028 (3)
What to watch
What to watch
What to watch
2029 (6)
February 2029 (1)
What to watch
April 2029 (1)
What to watch
June 2029 (1)
What to watch
November 2029 (2)
December 2029 (1)
What to watch
2030 (3)
February 2030 (1)
What to watch
April 2030 (1)
What to watch
June 2030 (1)
What to watch
2031 (1)
January 2031 (1)
What to watch
2032 (2)
2035 (1)
June 2035 (1)
What to watch
Regulatory and conference events
(10)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent